Trial intelligence / Profile preview

Q702 and Pembrolizumab in Advanced Solid Tumors

NCT05438420Phase 2

Key facts

Status: Active, not recruiting
Start: Jan 2023
Primary completion: Dec 2027
Countries: 2
Sponsor: Qurient Co., Ltd.
Modality: Small Molecules

Drugs: adrixetinib
Conditions: esophageal cancergastric cancer (GC)hepatocellular carcinoma (HCC)Cervical Cancer (CC)

Overview

Phase 2, open-label trial of adrixetinib in esophageal cancer, gastric cancer (GC), hepatocellular carcinoma (HCC) and 1 more (2 arms), sponsored by Qurient Co., Ltd. Primary endpoints: Treatment-related adverse events up to 2 years and Tumor response using RECIST version 1.1 up to 2 years. Started Jan 2023; status: active, not recruiting.

Design

2 arms

Study design: Non-randomizedOpen-label

Dose Escalation
Dose escalation of Q702 in combination with fixed dose of pembrolizumab
Dose Expansion
Dose expansion of Q702 in combination with fixed dose of pembrolizumab

Endpoints

Primary

Treatment-related adverse eventsUp to 2 years
Tumor response using RECIST version 1.1Up to 2 years

Secondary

Area Under the Curve of Q702 and its primary metabolitesCycle 1 Day 22

Beyond the preview

Go deeper on NCT05438420.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05438420.